A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
← catalyst calendarNCT04772079 · readout in 866 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
153estimated
Sites
65
Countries
Argentina, Australia, Brazil +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-23 | actual | When the study began enrolling |
| Primary completion | 2029-01-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-09-08 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Drug: Deucravacitinib
- Other: Placebo matching deucravacitinib
Primary outcomes
what the primary-completion date above is the date OFObserved average concentration at steady state for deucravacitinib at Week 2
measured Week 2
Maximum observed plasma concentration at steady state for deucravacitinib at Week 2
measured Week 2
Trough observed plasma concentration for deucravacitinib at Week 2
measured Week 2
Proportion of subjects with at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16
measured Week 16
Proportion of subjects with an static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16
measured Week 16
Incidence of Adverse Events (AEs)
measured Up to 316 weeks
Incidence of serious adverse events (SAEs)
measured Up to 316 weeks
Monitoring of growth: Body weight
measured Up to 316 weeks
Monitoring of growth: Height
measured Up to 316 weeks
Monitoring of growth: Tanner staging (sexual maturation)
measured Up to 316 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed